Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

Go back to Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom
(NASDAQ: MDGL) Delayed: 497.71 +4.09 (0.83%)
Previous Close $493.62    52 Week High $18.24 
Open $497.08    52 Week Low $6.60 
Day High $504.06    P/E N/A 
Day Low $478.71    EPS $0.00 
Volume 166,177